Index

Page numbers in *italics* refer to illustrations or tables.

A

abscess 51, 175
  drainage 113
  floor of the mouth *61*
  neonatal *115*
accessory parotid tissue 3, *4*, 208
  surgery 126, 210, 211
acini structure 4, *5*
acinic cell carcinoma (ACC) 36, *36*, 173, *174*, 264–265
  clinical features 265
  definition 264
  distant metastases 344
  epidemiology 264
  genetic alterations 254
  pediatric 97
  prognosis 265
  radiotherapy *309*
acquired immunodeficiency syndrome-related parotid cysts (ARPCs) 171
actinomycosis 118
adenocarcinoma 270, *276*
  basal cell 39, 257, *257*, 269, *283*, *290*, 303
  genetic basis 256–257
  mucinous 39, 270, 303
  oncocytic 39
  pediatric 97
  perineural spread *280*
  polymorphous low-grade (PLGA) 37, *37*, 256–257, 267, 302
  primary salivary 39
  radiotherapy *312*
adenoid cystic carcinoma (ACC) 36–37, *37*, 266–267, *277*, *279*, *291*
  clinical features 266, 316–317
  definition 266
  distant metastases 344, *347*
  epidemiology 266
  genetic basis 256
  pediatric 97
  prognosis 266–267
  radiotherapy 309–310, *310*, *311*
  recurrence *338*
  tumor patterns 266
adenoma
  basal cell 34, *34*, 196
    etiology 190
  canalicular 34, *34*, 196
  monomorphic 33–34
  plasmacytoid *33*, 34
  sebaceous 197
  see also pleomorphic salivary adenoma (PSA)
age, treatment choice and 304
aging 16
alcohol consumption 253
amifostine 427, 441
androgen receptors 469
anesthesia
  facial reanimation surgery 378, 382, 383, 385, 386, 389
  sialendoscopy 77, *77*, 139–140
  skin anesthesia following surgery 296
  surgical procedures 211, 288
    recurrent disease 236, 335
angiogenesis-related growth factor receptors 466–467
anterior opercular syndrome (AOS) 104
anterior triangle 329
antimicrobial therapy 113
aplasia 87
  of the lacrimal and salivary glands (ALSG) 7–8
apoptosis-related genes and proteins 342–343, 469
aquaporins 444–445
argyrophilic nucleolar organizer region–associated proteins (AgNOR) 463, 464–465
Armed Forces Institute of Pathology, Washington, DC 181–182
atrophy 27–28
  sialadenitis 29, *30*
autoantibodies, Sjögren syndrome 155–156, 157
autoclave 83
autoimmune sialadenitis
  see Sjögren syndrome

B

B cells, Sjögren syndrome 155
B-cell activating factor (BAFF) 155
bacterial sialadenitis 115–116, *127*
  prevention with xerostomia 127
balloons 143, *143*, 145
Bartholin duct 4
  see also duct system
Bartonella henselae 118
basal cell adenocarcinoma 39, 269, *283*, *290*
  clinical features 269
  definition 269
  genetic basis 257, *257*
  radiotherapy 303
basal cell adenoma 34, *34*, 196
  etiology 190
benign lymphoepithelial lesions (BLELs) 40, 53, 170, *170*
  treatment 170
biological agents 315, 319–320, *320*, 340
  bortezomib 320
  gefitinib (Iressa) 319
  imatinib (Gleevec) 319
  lapatinib 320
  recurrent disease 340
  trastuzumab 320
biopsy 44
  benign tumors 201–202
  core-needle biopsy 71
  pediatric pathology 96, 112
  sarcoidosis *162*
  Sjögren syndrome 157, *157*
biphasic luminal structures 32, *32*
bleeding, postoperative 295
blood supply 6
  embryology 8
blood tests, pediatric infectious conditions 111
bone invasion 279

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

bortezomib 320
botulinum toxin A injection
106–107, *107*
facial expression therapy 391
Frey syndrome therapy *396*, 397
salivary fistula therapy
394–395, *395*
side effects 107
xerostomia treatment
441–442, *442*
bougies 78, 143, 145
brain tumor metastases 376
branchial cleft cysts 90, 172
Brazil 182
breast carcinoma metastases 376
British Salivary Gland Tumor Panel
181, 248

C

calcifications 55, *56*
calcitonin gene-related peptide 15
calculi *see* sialolithiasis; sialoliths
canalicular adenoma 34, *34*, 196
cancer therapy *see* chemotherapy;
radiotherapy; tumors
candidosis, prevention with
xerostomia 127
cannulas 78
double-flow with working
channel 141, *141*
carcinoma 53
acinic cell (ACC) 36, *36*, 97, 173,
174, 264–265
adenoid cystic (ACC) 36–37, *37*,
97, 256, 266–267, *277, 279,*
291, 309–310, 316–317
clear cell 39, 269
epithelial–myoepithelial 37–38,
257, 269
genetic basis 255–256, 257–258
large cell 271
lymphoepithelial 39–40, 269
mammary analogue secretory
(MASC) 254–255, *254*
Merkel cell 371–372
mucoepidermoid 35–36, *36*, 97,
173, 255–256, 266
myoepithelial 258, 270
oncocytic 34–35, *35*, 39,
196, 267
pediatric 97
recurrent 99
salivary duct 38–39, *38*, 258,
258, 267–268, *278*, 302
sebaceous 269–270, 303
small cell 271
squamous cell (SCC) 39, *40*,
268, *277*
see also adenocarcinoma; tumors
carcinoma ex pleomorphic adenoma
38, *38*, 97, 258, 268
clinical features 268
definition 268
distant metastases 345
prognosis 268
tumor patterns 268
carcinosarcoma 270
cardiovascular disorders 24
cat-scratch disease 118, *118*
causation 458–459
cDNA microarrays 469
cell cycle oncogenes 468
cell cycle–based proliferation
indices 464–465, *464*
cell migration 469
cellular telephones 180
cell–cell adhesion 469
cervical lymph node metastases
see neck metastasis
cevimeline 126
chemokines, Sjögren syn-
drome 154–155
chemotherapy 315
combination therapy
318, 319, *319*
cytotoxic chemotherapy
317–318
diagnostic work-up 317
head and neck cancer 419
indications and patient selection
317, 340
metastatic disease 347
monotherapy 318, *318*, 319
outcomes and prognosis
320–321
patient information
and consent 340
recurrent disease 340
xerostomia and 420
children *see* pediatric disorders
China 182
chromosome translocations
188, 254
acinic cell carcinoma 254
adenoid cystic carcinoma 256
basal cell adenocarcinoma
257, *257*
carcinoma ex pleomorphic
adenoma 258
epithelial–myoepithelial
carcinoma 257
mammary analogue secretory
carcinoma (MASC) 254–255,
254
mucoepidermoid carcinoma
255–256
pleomorphic adenoma
188–189, *189*
polymorphous low-grade adeno-
carcinoma 257
chronic sclerosing sialadenitis
51–52, 152
see also Sjögren syndrome
clear cell carcinoma 39, 269
collecting ducts 5, *5*
computed tomography (CT) 44, 60
advantages and
disadvantages 60
before sialendoscopy 76, *76*
benign tumors 202
in emergency situation 60, *61*
malignant tumors 276–277
bone invasion 279
perineural spread 280
pediatric pathology 112
PET/CT 64
malignant tumors
275, 282–283, *283*
radiotherapy planning
226, 424–425
trauma 406
congenital abnormalities
see pediatric disorders
consent *see* informed consent
contrast medium 44
core-needle biopsy 71
covert mandibular swing 292, *292*
cyclin D1 468
cystadenocarcinoma 270
low-grade cribriform 270
papillary 303
cystadenoma 32, 173, 198
cystic fibrosis 24
cysts *30*, 53, 167
acquired 168–169
benign 170–171, *170*
branchial cleft 90, 172
classification 168–169, *168*
clinical features 169
congenital 168
conventional extravasation 31, *31*
cystic neoplasms 173–174, *174*
definition 167
dermoid 175
diagnostic work-up 169
errors in diagnosis 169
epidermoid 175
false 167

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

HIV-associated 171–172, *172*
lymphoepithelial 32, *114*
mucoceles 171
parapharyngeal 91
parasitic 169
parotid *112*
polycystic salivary disease of the parotid 32, 171
ranulas 172, *173*
retention 31–32, 168, 171
salivary duct 171
traumatic 174
true 167
cytokines, Sjögren syndrome 154–155
cytotoxic chemotherapy 317–318

D

deep vein thrombosis 296
degeneration secretion 15
dehydration 24
denervation phenomena 15
Denmark 183
dental caries *127*
prevention with xerostomia 126–127
depression 414
treatment 416
dermoid cyst 175
developmental abnormalities *see* pediatric disorders
digastric muscle *214, 218*
dilators 78
disease-specific survival (DSS), parotid carcinoma 351, *352*
diuretics 24
DNA damage repair 468–469
Dormia baskets 141, *142*
impacted stone 149
drainage
abscess 113
following interventional sialendoscopy 150
drooling 16, 49
botulinum toxin treatment 106–107, *107*
clinical features 103, *103*
definition 102
diagnosis 103–104
epidemiology and etiology 102–103
outcome and prognosis 107–108
pediatric 102–108
quality of life issues 414
surgical treatment 104–106, *105*
complications 106
duct ligation 105
duct relocation 105
gland removal 105–106
neurectomy 104–105
dry eyes 128–133
clinical features 128
definition 128
diagnostic work-up 128–129
differential diagnosis 129, *130*
epidemiology and etiology 128
outcome and prognosis 133
Sjögren syndrome 156
treatment 129–133, 415–416
future developments 133
lid margin disease 130–131
submandibular gland transplantation 431
surgery 133
tear preservation 130–131
tear replacement 130, *131–132*
topical treatment 129–133
dry mouth (xerostomia) 16, 21, 49, 123–127, *124*
causes *22, 125*, 439
drugs *22*, 23, 420
radiotherapy 23–24, 125, *125*, 230, 308, 419, 420–427, 439–440
Sjögren syndrome 23, 156, 157, *157*, 440–441
clinical features 123
complications of 126–127
bacterial sialadenitis 127, *127*
candidosis 127
dental caries 126–127, *127*
definition 123
diagnostic work-up 123–124, *124*
differential diagnosis 124–125
measurement 420–422
diffusion-weighted MRI 422
MR sialography 421–422
saliva flow measurements 420–421, *421*
scintigraphy 421
protection against with radiotherapy 424–427, 441
amifostine 427, 441
CT use in treatment planning 424–425
intensity-modulated radiotherapy (IMRT) 425–427
pilocarpine 427
proton therapy 427
quality of life impact 420, 422
treatment 126, 157–158, *158*, 440–448
experimental treatments 441–442, *442*
future trends 448
gene therapy-based approaches 444–445
stem cell-based salivary gland regeneration 445–448, *447*
tissue engineering 442–444, *443*
duct ligation 105
duct relocation 105
duct system 13–14, 73–74, *74*
Bartholin duct 4
collecting ducts 5
congenital abnormalities 87
cysts 31–32, 171
distribution within salivary glands 5, *5*
duct of Rivinus 4, *4*
intercalated ducts 5
salivary duct carcinoma 38–39, *38*, 267–268, *278*
genetic basis 258, *258*
stenoses 63, *63*
interventional sialendoscopy 138, 145
Stensen duct 3, *4*, 51, *138*
striated ducts 5
Wharton duct 4, *4*, 51, *139*
see also parotid duct; submandibular duct
ductal papilloma 35, 197–198
intraductal 197–198
inverted 197
ductal perforation 149
duty of care 455
dysfunctional tear syndrome *see* dry eyes
dysphagia, following radiotherapy 420

E

E-cadherin 342, 468
electromyographic (EMG) biofeedback therapy 391
electromyography 380
electrostimulation 391
embryology 6–8, *7*
bud stage 6–7
canalicular stage 8

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

innervation and blood vessels 8
myoepithelial cell development 8
pre-bud stage 6
pseudoglandular stage 7–8, *7*
terminal bud stage 8
embryoma 97
England 249
enlargement 47
epidermal growth factor receptor (EGFR) 315, *316*, 467
epidermoid cyst 175
epithelial-mesenchymal transition (EMT) 32, 33, 38, 468
epithelial-myoepithelial carcinoma 37–38, 269
genetic basis 257
radiotherapy 302
Epstein–Barr virus (EBV) 40, 187
salivary gland tumors and 187, 253
Ercc1 468–469
estrogen receptors (ERs) 253, 469
ethmoid sinus carcinoma 310, *312*
examination 42, *42, 43*, 49–50, *50*
benign tumors 201
saliva 42–43
serologic 45
sialendoscopy and 75, *76*
extracapsular dissection (ECD) 210, 215
patient information 211
extracorporeal lithotripsy 146, *146*

F

facial depression deformity 397–398, *398*
facial nerve 12, 205–206, *205, 206 218, 403*
branching *206*
children 91, *91*
failure to identify 220
function testing 406
location *205*
parotid gland surgery and 287, 289–290, *289, 290*, 337
facial nerve monitoring 212–213, *212*, 461
perineural tumor spread 280, *310*
prognostic significance of dysfunction 355, *356*
surgical dissection 216, *216*, 220
trauma 402, 407
trunk *91, 205, 214, 216*
see also facial reanimation surgery
facial nerve palsy 47–49, *291*, 295, 378
definition 393
diagnostic work-up 393–394
epidemiology and etiology 393
iatrogenic 393–394
management 394
decision-making algorithms *379, 380, 394*
medicolegal issues 460
compensation 461–462
facial nerve monitoring 461
see also facial nerve
facial reanimation surgery
adjuvant procedures 391
direct facial–facial nerve reconstruction 378–381
dynamic procedures with regional muscle transposition 386–388, *387*
facial–facial nerve interpositional graft 381–382, *381, 390*
free microvascular flaps 391
hypoglossal–facial nerve jump anastomosis 382–383, *384, 390*
static procedures with slings 388–389, *390*
upper eyelid surgery 385–386, *385*
facial vein *217*
fascia lata 389
fast-neutron therapy 307
fatigue 414
treatment 416
FDG-PET/CT *see* positron-emission tomography/computed tomography (PET/CT)
fibrosis, sialadenitis 29, *30*
fine-needle aspiration cytology (FNAC) 44, 66
benign tumors 201–202
capillary method 68
complications 69
contraindications 69–70
cystic lesions 169
diagnostic accuracy 70
equipment 67
fixation techniques 69
frozen-section diagnosis 70–71
informed consent 66
misdiagnoses 70, *70*
pediatric pathology 96, 111
physician 67
sensitivity 70
slide preparation 68–69, *68*
staining methods 69
suction FNAC 68
ultrasound-guided 67, *67, 68*
Finland 249
first branchial cleft anomalies 90–91
fistula *see* salivary fistula
fixation techniques 69
fluid secretion 13, *14*
focal lymphocytic adenitis (FLA) 27, *28*
focal obstructive adenitis (FOA) 27, *28*
Foix–Chavany–Marie syndrome 104
free abdominal fat grafts 294, *294*
free microvascular flaps 391
Frey syndrome 296, 395–397
definition 395–396
diagnostic work-up 397
epidemiology and etiology 396
therapy *395, 396, 397*
frozen-section diagnosis 70–71

G

gefitinib (Iressa) 319
gene therapy approaches 444–445, *444*
aquaporins 444–445
microvasculature 444
genetic basis of salivary gland tumors 188, 253–254
acinic cell carcinoma 254
adenoid cystic carcinoma 256
basal cell adenocarcinoma 257, *257*
basal cell adenoma 190
carcinoma ex pleomorphic adenoma 258
epithelial–myoepithelial carcinoma 257
mammary analogue secretory carcinoma (MASC) 254–255, *254*
mucoepidermoid carcinoma 255–256
myoepithelioma 190, 258
pleomorphic adenoma 188–189, *189*
polymorphous low-grade adenocarcinoma 257
Warthin tumor 189–190
genomics 343
giant cell granulomatous sialadenitis of the sublingual salivary gland 31
Gleevec 319

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

graft-versus-host disease (GVHD) 159–161
clinical features 160
definition 159
diagnostic work-up 161
epidemiology and etiology 160
outcome and prognosis 161
treatment 161
granuloma *117*
granulomatous infection 116–118
great auricular nerve *400*
growth factor receptor proteins and ligands 465–468
guide wires 78, 142
guided puncture technique 79, *79*
gustatory sweating syndrome 296, 395–397
definition 395–396
diagnostic work-up 397
epidemiology and etiology 396
therapy 397

H

head and neck cancer
chemotherapy 419
direct invasion of the parotid gland 372–373
parotid lymph-node metastases 372
radiotherapy 23–24, 419
hearing loss, radiation-induced 230, 308
heavy-ion therapy 307–308
hemangioma 53, 198
congenital *87*, 88–89
clinical features 88
treatment 88–89, *88, 89*
hematoma, following sialendoscopy 83
hemorrhage, postoperative 295
high-throughput analysis 469, *470*
history 46
HIV infection 163–164
cysts and 171–172, *172*
HIV parotitis 114
treatment 163–164
HMGA2 transcription factor 188, 189
hormonal influences 15
human epidermal growth factor receptor (HER) 467
human herpesvirus (HHV) 187
human papillomavirus (HPV) 187
human telomerase reverse transcriptase (hTERT) 463, 465
hydatid disease 169
hyperplasia 28
lymphoepithelial 198–199
multifocal nodular 28, *28*, 35, *35*
hypertrophy 28
hypesthesia following surgery 296
hypoglossal nerve *209*
injury 399–400
perineural tumor spread 280–281
hypoglossal–facial nerve jump anastomosis 382–383, *384, 390*
hyposalivation 21, 123
causes 124, *125*
see also dry mouth

I

imaging 55
before sialendoscopy 76
cystic lesions 169
malignant tumors 274–283, *276–279*
bone invasion 279
perineural spread 279–281, *280*
pediatric pathology 96, 112
see also specific imaging modes
imatinib (Gleevec) 319
incidence 247
benign tumors 183–185, *184*
distant metastases 343–346, *343, 345, 346*
malignant tumors 247, 248–250
neck metastases 324, *324*
India 182–183
infantile cerebral palsy (ICP) 104
infection 75
granulomatous 116
see also pediatric disorders; *specific infections*
inflammation 110
acute 51
chronic 59
definition 110
pediatric *see* pediatric disorders
Sjögren syndrome 154–156, *155*
see also parotitis; sialadenitis
informed consent 456–458
facial reanimation surgery 378, 381, 382–383, 385, 386
fine-needle aspiration cytology 66
interventional sialendoscopy 139, *140*
radiotherapy 226, 242, 339
salivary gland transplantation 432
surgery 210–211, 236, 288, 335
innervation 6, 12
denervation phenomena 15
development 8
efferent pathways 12
sensory innervation 15
insulin-like growth factor (IGF-IR) 467–468
integrins 342
intensity-modulated proton therapy (IMPT) 427
intensity-modulated radiotherapy (IMRT) 308–310, 425–426, *425, 426*
intercalated ducts 5, *5*
interferon (IFN), Sjögren syndrome 154–155
interventional sialendoscopy *see* sialendoscopy
intracranial tumor invasion 281
Iressa 319

J

Jawaharlal Institute of Postgraduate Medical Education, Pondicherry, India 182–183
jugular vein 329, 338

K

Karolinska Hospital, Stockholm, Sweden 181, 248
Kawasaki disease 119
keratoconjunctivitis sicca *130*
submandibular gland transplantation and 431
see also dry eyes
Ki-67 (MIB-1 antibody) 464, *464*
Kimura disease 119
Küttner tumor 29, 51–52, 152

L

lacrimo-auriculo-dento-digital (LADD) syndrome 7–8
lapatinib 320
large cell carcinoma 271
laser systems 142, *143*, 144–145
lingual nerve *209, 218*
injury 399–400

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

lipoma 198
lissamine green dye 129
lithiasis *see* sialolithiasis
lithiasis, stenosis, and dilation (LSD)
classification 80, *80, 81*, 138
local anesthesia
parotid gland 77
sialendoscopy 77, *77*
submandibular gland 77
see also anesthesia
Londrina Cancer Institute, Brazil 182
lung cancer metastases 375
lymphadenitis, acute pediatric 116
lymphadenoma, sebaceous 197, 270
lymphangioma 89, *89*
treatment 89–90, *89*
lymphoepithelial lesions
carcinoma 39–40, 269
clinical features 269
definition 269
epidemiology 269
prognosis 269
cysts 32, *114*
hyperplasia 198–199
Sjögren syndrome 154
lymphoepithelial sialadenitis (LESA) *29*, 30, *30*, 40
lymphoma *see* MALToma

M

magnetic resonance imaging (MRI) 44, 61–62
advantages and disadvantages 61
before sialendoscopy 76
benign tumors 202
diffusion-weighted MRI evaluation of salivary gland function 422
indications 62
malignant tumors 274–275, 277–282, *277–280*
bone invasion 279
intracranial invasion 281
new technologies 281–282
perineural spread 280
pediatric pathology 112, *112*
magnetic resonance sialography 44, 62–64
advantages and disadvantages 62
recurrent juvenile parotitis 64, *64*
sialolithiasis 62–63, *63*
Sjögren syndrome 64, *64*
stenoses 63, *63*
technique 62
xerostomia assessment 421–422
magnetic resonance spectroscopy (MRS) 282
malignant melanoma 372
malnutrition 24
MALToma *40*, 158–159, 174
clinical features 158–159
definition 158
diagnostic work-up 159
epidemiology and etiology 158
outcome and prognosis 159
Sjögren syndrome 40, 158
treatment 159
mammary analogue secretory carcinoma (MASC) 254–255, *254*
mandibulostyloid ligament 205
mandibulotomy approach 210, 216, 220
patient information 211
postoperative care 221
marginal zone B cell lymphoma of mucosa-associated lymphoid tissue *see* MALToma
masseter muscle transposition 388
matrix metalloproteinases (MMPs) 342
mealtime syndrome 75, *76*
MECT1-MAML2 oncogene 468
medicolegal issues 451
avoiding problems 459–460
causation 458–459
consent 456–458
duty of care 455
facial nerve paralysis 460
compensation for 461–462
facial nerve monitoring 461
negligence 451–453
steps in a medical negligence claim 453–454
no-fault compensation schemes 454–455
standard of care 455–456
melanoma, malignant 372
melatonin 16
Memorial Sloan-Kettering Cancer Center, New York 181, 248
Merkel cell carcinoma 371–372
mesenchymal stem cells 447–448
metaplasia 28
metastatic disease 54, 374, *374, 375*
brain tumor metastases 376
breast carcinoma metastases 376
chemotherapy indications 317
diagnostic work-up 317
distant metastases 341–348
diagnostic work-up 346–347, *347*
follow-up 346
frequency 343–346, *343, 345, 346*
treatment 347
intracranial invasion 281
lung cancer metastases 375
mechanisms of metastasis 341–343
apoptosis-related genes 342–343
E-cadherin 342
genomics and proteomics 343
integrins 342
matrix metallo-proteinases 342
RUNX3 343
vascular endothelial growth factor 343
metastasizing pleomorphic adenoma 270–271
neck 323–324, 323–331, *323*
cervical lymph-node treatment 98, 304–305, *305*
incidence 324, *324*
occult metastases 325, *325*
prognostic impact 323–324
recurrences 325–326, *326*
treatment 326–331, *330*
parotid lymph nodes 367–371, *368, 369*, 372–373
renal carcinoma metastases 375
skin cancer metastasis 367–371, *368, 369*
follow-up in high-risk patients 370–371
prognosis 369–370
risk factors 368–369, *369*
staging 370, *370*
treatment 371, *371*
submandibular gland 376
microliths 27, *28*, 29
Mikulicz disease 198
see also Sjögren syndrome
miniforceps 142, *142*, 144
mobile telephones 180
modified Blair incision 398–399, *399*
mouth-wetting agents 126
mucinous adenocarcinoma 39, 270, 303
mucins 19

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

mucoceles 31, 171
mucoepidermoid carcinoma 35–36, *36*, 173, 266
clinical features 266, 317
definition 266
distant metastases 345
epidemiology 266
genetic basis 255–256
pediatric 97
prognosis 266
mucosa-associated lymphoid tissue (MALT) lymphoma *see* MALToma
multidetector CT (MDCT) 60
multifocal nodular oncocytic hyperplasia 28, *28*, 35, *35*
multivariate survival analysis 352, *353*
mumps 113–114
Mycobacterium infection 116–117
M. tuberculosis 116
nontuberculous (NTM) 116–117, *117*
myoepithelial carcinoma 258, 270
clinical features 270
definition 270
prognosis 270
myoepithelial cells 6, 14
development 8
myoepithelioma 33, 190, 195–196
genetic basis 190, 258
myxoglobulosis 31

N

neck metastasis 323–324, 323–331, *323*
cervical lymph node treatment 98, 304–305, *305*
incidence 324, *324*
occult metastases 325, *325*
prognostic impact 323–324
recurrences 325–326, *326*
treatment 326–331
complications 331
modified neck dissection 329–330
node-negative neck 326–327
node-positive neck 326
radical neck dissection 330–331, *330*
selective neck dissection 327–329
necrotizing fasciitis *61*
necrotizing sialometaplasia 28, 198
negligence 451
definition 451–453
steps in a medical negligence claim 453–454
neonatal sialadenitis 115, *115*
neoplasms *see specific neoplasms*; tumors
nerve growth factor (NGF) 8
Netherlands 249
neurectomy 104–105
neurological neoplasms 174
neutron therapy 307
no-fault compensation schemes 454–455
nontuberculous mycobacterial (NTM) infection 116–117, *117*
nuclear factor κB (NFκB) 468

O

occupational exposure 253
oncocytoma 34–35, *35*, 39, 196, 267
clinical features 267
definition 267
radiotherapy 303
open mandibular swing 293, *293*

P

P values 352–355, *354*
p53 transcription factor 468
pain
control of 297
following sialendoscopy 83
palmaris longus tendon 389
papilloma *see* ductal papilloma
parapharyngeal space (PPS) 206–208, *207*
boundaries 206–207
parapharyngeal cysts 91
prestyloid space 207, *207*
retrostyloid/post-styloid space 207, *207*
revision surgery for recurrent tumors 241
transcervical/transparotid approaches 210, 215–216, *216*
parasympathetic denervation 104–105
parenchymal injury 406
paresthesia, ear region 399
parotid duct 205, 402, *403*
ectasia *112*
relocation 105
trauma 406, *406*
see also duct system
parotid glands 3, *4*, 51
accessory parotid tissue 3, *4*, 208
surgery 210, 211, 216
cysts *112*
HIV-associated 171, *172*
polycystic salivary disease of the parotid 32
diagnostic work-up 138–139
efferent pathways 12
local anesthesia 77, *77*
malignant tumors *276–279, 283*
disease-specific survival (DSS) 351, *352*
invasion by head and neck cancer 372
prognostic research 350–351
recurrence 334
treatment planning algorithm *287*
see also specific malignancies; tumors
metastases *see* metastatic disease; parotid lymph nodes
pediatric tumors 94
diagnosis 96
surgical treatment 97–98, *98*
radiotherapy 308, 309, *309, 310*
dose-response curves for complications 422–423, *423*
pilocarpine benefits 427
saliva characteristics 19
saliva production 4
stones, interventional sialendoscopy 144, 146–147, *147, 148*
surgery 211–216, 219–220, 287, 289–294, *289–294*
classification *212*
extracapsular dissection (ECD) 210, 211, 215
facial nerve and 212–213, *212*, 287, 289–290, *289, 290*
local tumor enucleation 289
mandibulotomy approach 210, 211, 216, 220
reconstruction 294, *294*
recurrent disease 336–338, *336–338*
transcervical/transparotid approaches 210, 215–216, *216*
transoral approach 291–293, *292–293*
see also parotidectomy; tumors
surgical anatomy 203–208
deep lobe 208
deep/medial lobe 204–205

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

facial nerve 205–206, *205, 206*
fibrous capsule 204
ligaments from the styloid process 205
location 203, *204*
parotid duct 205
superficial lobe 204
trauma 402–404
classification *405*
clinical features 404
diagnostic work-up 404–406, *404*
epidemiology 404
treatment 406–407
see also parotid duct; Stensen duct
parotid lymph nodes 367
head and neck cancer metastases 372
skin cancer metastasis 367–371, *368, 369*
follow-up 370–371
prognosis 369–370
risk factors 368–369, *369*
staging 370, *370*
treatment 371, *371*
parotid papilla 3, 74
parotidectomy
accessory parotid tissue 210, 211, 216
choice of procedure 287
facial nerve and 287, 289–290, *289, 290*
lateral/superficial 210, 213–215, *213–215*, 289
partial 210, 215
radical 290–291, *291*
reconstruction 294, *294*
revision parotidectomy *237, 238*, 239, 336–338, *336–338*
total 290, *290*
transoral approach 291–293, *292–293*
see also parotid glands
parotitis
acute parotitis of infancy 115, *115*
acute viral 113–114
HIV parotitis 114
mumps 113–114
recurrent juvenile 46, *47, 112*, 115–116
MR sialography 64, *64*
pharyngeal infiltration 149–150
sialendoscopy 81, 116, 138
treatment 116
patient history 46
pediatric disorders
congenital and developmental abnormalities 87–91
diagnostic work-up 87
epidemiology 87
first branchial cleft anomalies 90–91
hemangiomas *87*, 88–89, *88, 89*
salivary gland aplasia 87
vascular malformations 88, 89–90, *89*, 198
drooling 102–108
botulinum toxin treatment 106–107, *107*
clinical features 103, *103*
diagnosis 103–104
epidemiology and etiology 102–103
outcome and prognosis 107–108
surgical treatment 104–106, *105*
inflammatory and infectious diseases 110–119
clinical features 111
diagnostic work-up 111–113
epidemiology and etiology 110, *111*
treatment 113
recurrent juvenile parotitis 46, *47, 112*, 115–116
MR sialography 64, *64*
pharyngeal infiltration 149–150
sialendoscopy 81, 116, 138
salivary gland neoplasms 93–100, *94*
clinical features 95
diagnostic work-up 96–97
differential diagnosis 94–95, 96
epidemiology and etiology 93
outcomes and prognosis 99–100
recurrent neoplasms 99
treatment *95*, 97–99
salivary gland surgery 91
perineural tumor spread 279–281, *280*
facial nerve 280, *310*
hypoglossal nerve 280–281
trigeminal nerve 280
vagal nerve 281
photon therapy 307
physiotherapy, facial reanimation 390
picibanil sclerotherapy, vascular malformations 89–90
pilocarpine 126
preservation of parotid function 427
PLAG1 transcription factor 188–189, 468
plasmacytoid adenoma *33*, 34
pleomorphic salivary adenoma (PSA) 32–33, *33*, 52–53, *53, 96*, 173, 194–195, *278*
clinical presentation 194, 224
atypical 195
definition 194
etiology 188–189
"ghost" of 38, *38*
macroscopic pathology 194
metastasizing 270–271, 345
outcome and prognosis 228–230, *229*
radiotherapy 224, 225
recurrent PSA 228, 229–230, 233–234, *235*
diagnostic work-up 234
epidemiology and etiology 233–234
surgical management *238*, 239–241, *240*
surgical treatment 195, 224–225, *238*
plexiform neurofibroma 174
Poland 183
polycystic salivary disease of the parotid 32, 171
polymorphous low-grade adenocarcinoma (PLGA) 37, *37*, 267
clinical features 267
definition 267
epidemiology 267
genetic basis 257
prognosis 267
radiotherapy 302
tumor patterns 267
positron-emission tomography/computed tomography (PET/CT) 64
malignant tumors 275, 282–283, *283*
post-styloid space 207, *207*
posterior triangle 330
postoperative care
facial reanimation surgery 380, 383, 386, 388, 389
salivary gland transplantation 434, *435*
sialendoscopy 83, 150

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

tumor surgery 221, 296–297
radiotherapy 295, 305–306, *309*
revision surgery 242
prestyloid space *206*, 207
probes 78
progesterone receptors (PRs) 253, 469
prognostic index *353*
development *353–356*, 355–357
limitations of the current system 361–362
prognostic score 1 (PS1) 356
prognostic score 2 (PS2) 357
validation 357–360
clinical usefulness 359
clinical validation 357–359, *358*
examples of use 359–360, *360, 361*
independent sample 357
statistical validation 359, *359*
prognostic research 350–351
future developments 362–363
univariate and multivariate survival analysis 352
proliferating cell nuclear antigen (PCNA) 463, 464–465
proteins
composition of saliva 20, *20*
secretion 13
proteomics 343
proton radiotherapy 307, 427
pseudolymphomas 119

Q

quality of life 410
definition 410–411
dimensions of 410, *410*
improvement 415–416
depression treatment 416
fatigue treatment 416
sialorrhea treatment 416
xerostomia treatment 415–416
measurement 411–414
challenges 413–414, *413*
tools 411–413, *411–412*
problems in specific diseases 414–415
benign tumors 415
malignant tumors 415
Sjögren syndrome 414
xerostomia impact 422
questionnaires 411–413, *411–412*

R

radiation exposure, tumor risk and 179, 187, 252
see also radiotherapy
radiation otomastoiditis 308
radiography 55, 75
radionuclide scanning 57–58
radiotherapy 23–24, 224, 301
complications 230–231, 242, 308
audiovestibular problems 230, 308
dose-response curves 422–424, *423*
dysphagia 420
mechanisms of damage 440
morphological aspects 439–440
otomastoiditis 308
radiation-induced malignancy 230–231
radiation-induced toxicities 231
vascular problems 230
visual 308
xerostomia 23–24, 125, *125*, 230, 308, 419, 420–427, 439–440
dose 228
future directions 311
head and neck cancer 419
indications 304–305, *305*
cervical nodes 304–305
local treatment 304
site-specific indications 305
informed consent 226, 242, 339
patient information 226, 242
patient selection 225, 242, 301–304, 339
age 304
comorbidity 303, *304*
histological classification 302–303
prognostic factors 301
pediatric neoplasms 98–99
pleomorphic salivary adenoma (PSA) 224, 225
outcome and prognosis 228–230, *229*
postoperative 295, 305–306, *309*
recurrent disease
benign tumors 242
malignancies 333–334, 339–340
results 305–308
salivary gland protection 231, 424–427, 441
amifostine 427, 441
CT use in treatment planning 226, 424–425
intensity-modulated radiotherapy (IMRT) 308–310, 425–426, *425, 426*
pilocarpine 427
proton therapy 307, 427
submandibular gland transfer 432
techniques 226, *227*, 231, 242, 308–310, 339–340
conformal techniques 308–310, 425
conventional techniques 308–310, 424
determination of radiation fields 308
ranulas 172, *173*
RAS genes 468
reanimation surgery *see* facial reanimation surgery
recurrent disease
benign tumors 233–242
surgical management 236–241, *237–238, 240*
Warthin tumor 233, 234, 236
malignancies 333–340
chemotherapy 340
diagnostic work-up 334–335
epidemiology and risk factors 334
pediatric 99
radiotherapy 242, 333–334, 339–340
surgical treatment 333–334, *333*, 335–339, *336–338*
neck metastases 325–326, *326*
pleomorphic salivary adenoma 228, 229–230, 233–234, *235*
recurrent juvenile parotitis 46, *47, 112*, 115–116
MR sialography 64, *64*
sialendoscopy 81, 116, 138
pharyngeal infiltration 149–150
treatment 116
renal cell carcinoma (RCC) metastases 375
retention cysts 31–32, 168
mucoceles 171
retrostyloid space 207, *207*
“Roman bridge” pattern 38, *38*
Rosai–Dorfman disease 119
rose bengal dye 129

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

runt-related transcription factor-3 (*RUNX3*) 343

S

saliva 19
collection procedures 21
cultures 111
diagnostic significance 25
duct system influence 13–14
examination 42–43
excess 16, 49
functions 10–11, *10*
ion composition 19, *20*
stimulation effect 19–20
production 4
disturbances *48*, 49
stimulants 126, *126, 158*
protein composition 20, *20*
regulation 10, 11–12, *11*
see also salivary glands
secretion 11–12, *20*
fluid 13, *14*
protein 13
reflex 11–12
spontaneous 11
stimulation effect 19–20, *20*
saliva substitutes 126, *158*
salivary centers 12
input *11*
salivary duct carcinoma 38–39, *38*, 267–268, *278*
clinical features 268
definition 267
distant metastases 345
genetic basis 258, *258*
prognosis 268
radiotherapy 302
salivary ducts *see* duct system
salivary fistula 296, 394–395
definition 394
diagnostic work-up 394
late trauma sequelae 408, *408*
therapy 394–395, *395*
salivary flow rate 124, *124*
measurements 420–421, *421*
diffusion-weighted MRI 422
MR sialography 421–422
scintigraphy 421
stimulation 126, *126, 158*
salivary glands
biopsy 44
blood flow 14
blood supply 6
denervation effects 431
diseases affecting function 21–24, *22*
cardiovascular disorders 24
cystic fibrosis 24
malnutrition 24
Sjögren syndrome 23
water and salt balance disorders 24
drug effects on *22*, 23
hormonal influences 15
innervation 6, 12
sensory innervation 15
neural control 12–14, *13*
duct system influence 13–14
fluid secretion 13, *14*
protein secretion 13
normal structural variations 27–28, *28*
radiotherapy effects on 23–24
scintigraphy 45
stem cell-based regeneration 445–448, *447*
mesenchymal stem cells 447–448
stem cell isolation 446–447, *447*
tissue engineering 442–444, *443*
transplantation *see* transplantation
warm ischemic tolerance 431
weight 15–16
see also parotid gland; sublingual gland; submandibular gland
salivary incontinence *see* drooling
salivary stimulants 126, *126, 158*
Salivette method 21
sarcoidosis 31, 118, 161–163, *162*
clinical features 162
definition 161
diagnostic work-up 162
epidemiology and etiology 161–162
outcome and prognosis 163
treatment 162
scar cosmesis 398–399, *399*
Schirmer test 129
schwannoma 174
scintigraphy 45
xerostomia assessment 421
sclerotherapy, vascular malformations 89–90
sebaceous adenoma 197
sebaceous carcinoma 269–270, 303
sebaceous lymphadenoma 197, 270
sensory innervation 15
serologic examinations 45
sialadenitis
bacterial 115–116, *127*
prevention with xerostomia 127
chronic 51–52, *56, 217*
punctate 198
sclerosing 51–52, 152
see also Sjögren syndrome
conventional chronic obstructive 28–29, *29, 30*
lymphoepithelial (LESA) *29*, 30, *30*, 40
neonatal 115, *115*
serology 45
submandibular *61*
ultrasonography *58*, 59, *59*
sialadenoma papilliferum 35, 198
sialadenosis 28, 52
sialendoscopes 78
sterilization 83
therapeutic 141
sialendoscopy 44, 73
anatomy 73–74
anesthesia 77, 139–140
diagnostic
complications 82–83
contraindications 82
definition 73
diagnostic work-up 75–76, *76*, 138–139
patient selection 74–75
postoperative care 83
procedural steps 79–80, *79, 80*
rinsing during 80
equipment 78, *78*, 141–143
findings 80–82
dilation 81
lithiasis 81, *81*
obstructive pathologies 80–81, *80, 81*
recurrent juvenile parotitis 81
Sjögren syndrome 82
stenosis 81
imaging before 76, 138–139
interventional 73, 136
complications 149–150
definition 136
indications 137–138
patient information and consent 139
patient selection *137*
postoperative care 150
procedural steps 143–149
recurrent juvenile parotitis 116, 138, 149–150

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

salivary duct stenosis 138, 145
sialolithiasis 137, *137*, 143–145, 146–149
learning 77
pediatric pathology 113
sialoblastoma 97, 271
sialocele 394
late trauma sequelae 407–408
sialodochitis *56*, *63*
sialogogues 126, *126*
sialography 44, 56–57, *56*
advantages and disadvantages 57
before sialendoscopy 76
contraindications 57
contrast medium 44
indications 56
MR sialography 44, 62–64
xerostomia assessment 421–422
parotid trauma 404, *404*, 405
pediatric pathology 112–113, *112*
technique 56
sialolithiasis 52
lithiasis, stenosis, and dilation (LSD) classification 80, *80, 81*
MR sialography 62–63, *63*
sialendoscopy 81, *81*, 137, *137*, 143–145, 146–149
combined approach 146–149
complications 149–150
preoperative extracorporeal lithotripsy 146, *146*
submandibular *61*
ultrasonography 58–59, *58*
sialoliths 29, *30, 52*
sinuses 90, *90*
ethmoid sinus carcinoma 310, *312*
Sjögren syndrome 23, 52, 152–158, *156*, 414
American–European consensus criteria (AECC) 152–154, *153*
childhood 118
clinical features 156
definition 152
diagnostic work-up 156–157
epidemiology 152
etiology 152, 154–156, *154*
examination 42, 44, 52
lymphoepithelial sialadenitis 30
MALToma 40, 158
MR sialography 64, *64*
outcome and prognosis 158
quality of life issues 414
secondary Sjögren syndrome 154
serology 45
sialendoscopy 82
treatment 157–158
ultrasonography 59, *60*
xerostomia and 23, 124–125, 156, 157, *157*, 440–441
skin cancer
malignant melanoma 372
Merkel cell carcinoma 371–372
metastasis *see* metastatic disease
slide preparation 68–69, *68*
small cell carcinoma 271
smoking 179–180, 188, 253
sodium retention syndrome 24
SOX4 cell cycle oncogene 468
spinal accessory nerve (SAN) 328, 329
squamous cell carcinoma (SCC) 39, *40*, 268, *277*
clinical features 268
definition 268
stage grouping 264, *265*
staining methods 69
standard of care 455–456
stem cell factor receptor (c-Kit) 465–466
stem cell-based salivary gland regeneration 445–448, *447*
mesenchymal stem cells 447–448
stem cell characteristics 445–446
stem cell isolation 446–447, *447*
stenoses 63, *63*
lithiasis, stenosis, and dilation (LSD) classification 80, *80, 81*
sialendoscopy 81
interventional 138, 145
Stensen duct *56, 63*
Stensen duct 3, *4*, 51, *138*
sialadenitis and *56, 63*
stone removal 146–147, *147, 148*
see also duct system; parotid gland
stenting 143, 150
sternocleidomastoid muscle *214*
rotation flap 294, *294*
stones *see* sialolithiasis; sialoliths
striated ducts 5, *5*
stylomandibular ligament 205
stylomastoid artery 219–220
sublingual fold 4
sublingual gland 4, *4*, 51
saliva production 4
surgery 210, 218–219, 220, 294–295
patient information 211
surgical anatomy 209, *209*
submandibular duct 208–209
relocation 105
see also duct system
submandibular gland 4, *4*, 51
diagnostic work-up 139
local anesthesia 77
metastatic disease 376
pediatric tumors 94
diagnosis 96
surgical treatment 98
radiotherapy 308, 309, *311*
dose-response curves for complications 423
recurrent malignancies 334
removal 105–106
saliva production 4
stones, interventional sialendoscopy 144, 148–149, *149*
surgery 210, 216–218, *217–219*, 220, 288, 294–295
patient information 211
revision surgery 241
surgical anatomy 208–209, *209*
deep lobe 208
submandibular duct 208–209
superficial lobe 208
transplantation 430
indications 431–432
operative steps 432–434, *433–434*
postoperative care 434, *435*
see also transplantation
see also submandibular duct; Wharton duct
submandibular papillae 74, *74*
submandibular triangle 329–330
salvage surgery 339
substance P 15
supersensitivity 15
survival
disease-specific (DSS) 351, *352*
univariate and multivariate analysis 352, *353*
Sweden 181, 249
swelling
painful 46, *47*
painless enlargement 47

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

T

tear film 128
  tear preservation 130–131
  tear replacement 130, *131–132*
  see also dry eyes
Tear Function Index (TFI) 129
temporalis muscle transposition 386–388, *387*
terminal deoxynucleotidyl transferase (TdT)–mediated dUTP-biotin nick end labeling (TUNEL) 463, 465
tissue engineering 442–444, *443*
tissue inhibitors of metalloproteinase (TIMPs) 342
tissue microarrays 469
TNM classification 264, *265*
TP53 gene 342–343
tracheotomy 297
traditional Chinese medicine 441, *442*
transplantation 430–436
  complications 435, *435*
    measures of 435–436
  definition 430
  denervation effects on salivary glands 431
  diagnostic work-up 432
  indications 431–432
    keratoconjunctivitis sicca 431
    postradiation xerostomia prevention 432
  operative steps 432–434
    gland reduction 434, *434*
    gland transfer 433, *433, 434*
    preparation of recipient temporal area 432–433, *433*
    submandibular gland harvesting 432, *433*
  outcome 436
  patient information and consent 432
  postoperative care 434, *435*
  regulation of secretory function 430–431
  warm ischemic tolerance of salivary tissue 431
trastuzubam 320
trauma 402–404
  blunt 403, 406
  classification *405*
  clinical features 404
  cyst formation 174
  diagnostic work-up 404–406
    clinical assessment 404–405, *404*
    CT imaging 406
    facial nerve function testing 406
    sialography 404, *404*, 405
  epidemiology 404, 407
  facial nerve 402, 407
  late sequelae 407–408
    management 407–408
    types of 407
  parenchymal injury 406
  parotid duct injury 406, *406*
  penetrating 403, 406
  treatment 406–407
trigeminal nerve, perineural tumor spread 280
tuberculosis 116
tumorigenesis
  cell cycle–based proliferation indices 464–465, *464*
  elements of the cascade 465–469
    cell cycle oncogenes 468
    estrogen, progesterone, and androgen receptors 469
    growth factor receptor proteins and ligands 465–468
    proteins involved in apoptosis 469
    proteins involved in cell–cell adhesion, migration, and epithelial–mesenchymal transition 468
    proteins involved in DNA damage repair 468
  future developments 470
  high-throughput analysis 469, *470*
  mechanisms *466*
tumors
  benign 52–53, 179, *193*, 200
    classification 180, 193–194, *194*
    clinical features 200–201
    data 180–183
    diagnostic work-up 201–202
    etiology 179–180, 187–191
    incidence reports 183–185, *184*
    investigation algorithm *200*
    quality of life issues 415
    recurrent tumors 233–242
  capsular rupture 220–221
  epithelial 32–40, 94
  malignant 35–40, 53–54
    bone invasion 279
    classification 262, *263*, 264, *265, 351*
    clinical features 316–317
    comorbidity 303, *304*
    databases and population-based studies 249–250, *250*
    epidemiology 247–251, 315
    etiology 252–258, 315
    histogenesis 262–264, *264*
    imaging 274–283, *276–279*
    institutional studies 248–249
    intracranial invasion 281
    molecular biology 315, *316*
    perineural spread 279–281, *280, 310*
    problems with published epidemiological data 247–248
    quality of life issues 415
    see also metastatic disease; recurrent disease; *specific malignancies*; tumorigenesis
nonlymphoid mesenchymal (NLMTs) 95
nonsurgical treatment *see* chemotherapy; radiotherapy
pediatric neoplasms 93–100
  clinical features 95
  diagnostic work-up 96–97
  differential diagnosis 94–95, 96
  epidemiology and etiology 93
  outcomes and prognosis 99–100
  recurrent 99
  treatment *95*, 97–99
seeding 69, *69*
surgical management 202, 203–222, 285–299
  anesthesia 211, 236, 288, 335
  benign recurrent disease 236–241, *237–238, 240*
  choice of procedure 287–288
  classification of surgical interventions *286*
  complications 220–221, 241, 295–296, 335
  follow-up 298
  indications 210, 285–286
  outcomes 221, 297, *298*
  parotid gland 211–216, *212–216*, 287, 289–294, *289–294*
  patient information and consent 210–211, 236, 288, *288*, 335

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG

patient positioning 211, 288–289, 335
patient selection 210, 236, 285–286, 335
postoperative care 221, 242, 295, 296–297, 335
quality assurance 297
recurrent malignancies 333–334, *333*, 335–339, *336–338*
sublingual gland 218–219, 294–295
submandibular gland 216–218, *217–219*, 294–295
surgical anatomy 203–210
tips 219–220
see also cysts; *specific tumors*; tumorigenesis

U

ultrasonography 43–44, 50–51, 58–60
before sialendoscopy 76
fine-needle aspiration cytology guidance 67, *67*, *68*
pediatric pathology 112, *112*
sialadenitis *58*, 59, *59*
sialolithiasis 58–59, *58*
tumors 59–60, 201
malignancies 275–276, *276*
United Kingdom 181, 183–185
United States 181–182, 183, 249–250
univariate survival analysis 352
unstimulated whole saliva flow rate (USFR) 124
upper eyelid surgery 385–386, *385*

V

vagal nerve, perineural tumor spread 281
vascular endothelial growth factor (VEGF) 315, 466
metastases and 343
protection against radiotherapy-induced damage 444
vascular malformations 88, 89–90, *89*, 198
definition 89
treatment 89–90, *89*
viral infection
acute viral parotitis 113–114
HIV parotitis 114
mumps 113–114
salivary gland tumors and 187, 253
see also specific viruses

W

Warthin tumor 34, *35*, 53, *53*, 173, *174*, 195
clinical features 195
definition 195
diagnosis 195
etiology 187, 189–190, *190*
smoking 188
recurrent 233, 234, 236
diagnostic work-up 236
epidemiology and etiology 234
treatment 195
Wharton duct 4, *4*, 51, *139*
papillae *74*
stone removal 148–149, *149*
submandibular gland transplantation and 430, 432–434, *433*
see also duct system; submandibular gland

X

xerostomia *see* dry mouth

Bradley/Guntinas-Lichius, Salivary Gland Disorders and Diseases: Diagnosis and Management
(ISBN 9783131464910), © 2011 Georg Thieme Verlag KG